Published in Cancer on February 27, 2014
Ramucirumab in metastatic renal cell carcinoma: The beginning or the end? Cancer (2014) 1.40
Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med (2014) 1.24
Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. MAbs (2014) 0.85
Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int (2015) 0.80
Therapeutic challenges in renal cell carcinoma. Am J Clin Exp Urol (2015) 0.80
Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis. Oncotarget (2016) 0.75
Sex difference in EGFR pathways in mouse kidney-potential impact on the immune system. BMC Genet (2016) 0.75
Angiotensin II increases glomerular permeability by β-arrestin mediated nephrin endocytosis. Sci Rep (2016) 0.75
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst (2007) 5.13
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol (2007) 4.40
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (2005) 3.28
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol (2002) 3.05
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol (2008) 3.00
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol (2009) 2.69
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer (2013) 2.61
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol (2011) 2.46
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol (2008) 2.40
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol (2004) 2.37
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol (2009) 2.26
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol (2009) 2.23
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol (2003) 2.12
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol (2011) 2.10
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int (2011) 2.07
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol (2011) 2.02
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol (2012) 2.00
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res (2009) 1.93
Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl (2004) 1.88
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol (2012) 1.78
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol (2008) 1.74
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer (2011) 1.70
Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology (2010) 1.70
Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer (2009) 1.70
An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res (2008) 1.68
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica (2006) 1.67
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) (2010) 1.66
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant (2006) 1.63
Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology (2007) 1.63
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma. Clin Cancer Res (2005) 1.59
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A (2012) 1.58
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol (2002) 1.56
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J Magn Reson Imaging (2004) 1.54
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer (2010) 1.52
Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One (2009) 1.51
Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Magn Reson Med (2004) 1.50
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46